Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...

T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...

CAR T-cell therapy is a type of immunotherapy used to treat multiple myeloma when other therapies have failed. It has improved remission and survival times, but long-term data on safety and success is ...

Dr. Sham Mailankody says the new type of CAR T cell therapy could enable people with multiple myeloma to receive treatment faster. The first off-the-shelf (allogeneic) CAR T cell therapy for multiple ...

A hallmark characteristic of CAR T therapy is that it is individually crafted. Each patient receives a unique cancer-fighting infusion made from their own immune cells. The crucial process of ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma. In 2021, the FDA approved idecabtagene vicleucel (ide ...

A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy ...

A "living drug," CAR T involves removing cells from the body, modifying them, and finally reinfusing them into the body to fight cancer. This is the third installment in a series on the advances CAR T ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...

CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Elouise Wrisper’s cancer journey began with persistent back pain. It was 2021, and the retired teacher, who was active in ...

B-cell maturation antigen (BCMA)-directed CAR T-cell therapies are now established options for treating multiple myeloma after relapse, but efforts are underway to expand their use and to bring novel ...